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We previously reported the identification of a novel antimitotic agent with carbazole and 
benzohydrazide structures: N′-[(9-ethyl-9H-carbazol-3-yl)methylene]-2-iodobenzohydrazide (code 
number NP-10). However, the mechanism(s) underlying the cancer cell-selective inhibition of mitotic 
progression by NP-10 remains unclear. Here, we identified NP-10-interacting proteins by affinity 
purification from HeLa cell lysates using NP-10-immobilized beads followed by mass spectrometry. 
The results showed that several mitosis-associated factors specifically bind to active NP-10, but not 
to an inactive NP-10 derivative. Among them, NUP155 and importin β may be involved in NP-10-
mediated mitotic arrest. Because NP-10 did not show antitumor activity in vivo in a previous study, 
we synthesized 19 NP-10 derivatives to identify more effective NP-10-related compounds. HMI83-2, 
an NP-10-related compound with a Cl moiety, inhibited HCT116 cell tumor formation in nude mice 
without significant loss of body weight, suggesting that HMI83-2 is a promising lead compound for the 
development of novel antimitotic agents.
Faithful segregation of duplicated chromosomal DNA is essential to maintain genome integrity. The process is exe-
cuted by the mitotic spindles composed of the spindle microtubules and centrosomes under the control of mitotic 
kinases such as Cdk1, Aurora kinases, and Polo-like kinases (Plks). In addition, many microtubule-associated 
proteins (MAPs) including the kinesin and dynein are required for faithful chromosome segregation. The mitotic 
spindles are among the most successful targets of anticancer chemotherapy, and they remain promising targets 
of novel anticancer drugs1–4.
Taxanes, vinca alkaloids, epothilones, and halichondrins are representative antimitotic drugs used in clini-
cal practice, which are all tubulin-binding molecules and impede precise tubulin polymerization. While these 
antimitotics are effective for cancer treatment, some critical problems remain to be solved. For example, innate 
or acquired resistance to these agents is often observed. As microtubules also play a role in non-dividing cells 
including neuronal cells, these microtubule-targeting drugs perturb some important cellular processes in such 
cells, leading to side effects such as peripheral neuropathy. Therefore, a great deal of effort is underway to develop 
novel antimitotics that target non-tubulin mitotic factors such as Plks, Aurora kinases, CENP-E, and Eg51–4.
We previously reported the identification of novel antimitotic agents with carbazole and benzohydrazide 
structures including N′-[(9-ethyl-9H-carbazol-3-yl)methylene]-2-iodobenzohydrazide (code number NP-10), 
N′-[(9-ethyl-9H-carbazol-3-yl)methylene]-4-iodobenzohydrazide (code number NP-14), and N′-[(9-ethyl-
9H-carbazol-3-yl)methylene]-2-methylbenzohydrazide (code number HND-007). Among them, NP-14 and 
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HND-007 inhibit tubulin polymerization in vitro, suggesting that mitotic arrest in cells treated with these com-
pounds is partly due to such inhibitory activity against tubulin polymerization5. However, NP-10 does not sup-
press the tubulin polymerization, and microtubule formation is only partially inhibited in NP-10-treated cells5. 
In addition, NP-10 does not affect the kinase activity of Aurora B, Plk1, and Cdk1, or the ATPase activity of the 
CENP-E, Eg5, and KIFC1 kinesins5. The mechanism(s) underlying the cancer cell-selective inhibition of mitotic 
progression by NP-10 remains unclear. Here, we addressed this issue by identifying NP-10-interacting proteins 
by affinity purification from HeLa cell lysates using NP-10-immobilized beads followed by mass spectrometry. 
The results showed that several mitosis-associated factors specifically bind to active NP-10, but not to an inac-
tive NP-10 derivative. Further analysis suggested that NUP155 and importin β are involved in NP-10-mediated 
mitotic arrest.
Materials and Methods
Cell culture. HeLa cells were obtained from JCRB Cell Bank (JCRB9004, authenticated by STR-PCR). 
HCT116 cells were obtained from ATCC. HEK293T cells were obtained from Dr. Masao Seto, Aichi Cancer 
Center Research Institute, HFF2/T (normal human fibroblasts immortalized by telomerase) cells were established 
in-house5. They were grown in Dulbecco’s modified Eagle’s medium supplemented with 8% fetal calf serum and 
antibiotics. HFF2/T/E7/KRAS G12V cells overexpressing the E7 of human papilloma virus type 16 and the acti-
vated KRAS mutant G12V were established previously6 and grown in the same medium.
Growth inhibition assay. Growth inhibition assay was carried out essentially as described previously5. 
Briefly, cells were plated in 96-well plates at a density of 5 × 103 cells/well for 24 h and then treated with the indi-
cated compounds dissolved in DMSO for 48 h. Control cells were treated with DMSO at a final concentration of 
1%. MTS/PMS solution (CellTiter Aqueous Non-Radioactive Cell proliferation Assay, #G5430, Promega) was 
then added, cells were further incubated for 1 h, and OD490 was measured to determine the number of viable cells. 
The percent inhibition was estimated for each drug concentration, and the IC50 value was calculated from the 
linear portion of the dose-response curve using regression analysis.
For Fig. 1B, transfected HeLa cells (see below) were replated on 12-well plates (800 cells/well) in medium 
containing NP-10 at various concentrations. After 7 days, colonies were stained with Giemsa solution (Wako 
Pure Chemical Industries). For Fig. 2, HFF2/T and HFF2/T E7/KRAS G12V cells were seeded on 12-well plates 
at a density of 400 cells/well in medium containing NP-10 at various concentrations. After 8 days, colonies were 
stained with Giemsa solution. The percentage inhibition at each drug concentration was estimated. The IC50 value 
was then calculated from the linear portion of the dose-response curve using regression analysis.
Figure 1. Overexpression of NUP155 MC (aa 748–1391) confers partial resistance to NP-10 cytotoxicity in 
HeLa cells. (A) HeLa cells were transfected with the indicated expression vectors for 48 h and immunoblotted 
with anti-GFP antibody. Proteins were stained with Coomassie Brilliant Blue (CBB) to check equal loading. (B) 
HeLa cells were transfected with the indicated expression vectors for 24 h and subjected to colony formation 
assays in the presence of NP-10 at various concentrations. IC50 values were calculated. Data represent the 
mean ± SD from nine independent experiments. ***p < 0.001 (two-tailed Student’s t-test).
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Cell cycle analysis. Cell cycle analysis was carried out essentially as described previously5. Briefly, cells were 
treated with the indicated compounds for 24 h, and then suspended in phosphate-buffered saline (PBS) contain-
ing 0.1% TritonX-100, RNase (10 μg/mL), and propidium iodide (40 μg/mL). Cell cycle distribution was exam-
ined using a FACSCalibur or FACSVerse flow cytometer (BD Bioscience).
Synthesis of biotinylated NP-10 and NP-14 derivatives and HMI83-2. The following compounds 
were synthesized for affinity purification of the binding proteins from HeLa cell lysates (Fig. 3A): 1-(1-(13-Oxo-17-
((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-triazol-
4-yl)-2,5,8,11-tetraoxatridecan-13-yl (Z)-N-((E)-(9-ethyl-9H-carbazol-3-yl)methylene)-2-iodobenzohydrazonate, 
which is O-PEGylated NP-10 linked to PEGylated biotin via 1,2,3-triazole moiety (code number HMI1347); 
N-(2-(2-(2-(2-(4-((E)-1-(9-ethyl-9H-carbazol-3-yl)-3-(2-iodobenzoyl)-6,9,12,15-tetraoxa-2,3-diazahexadec-1-en-
16-yl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]
imidazol-4-yl)pentanamide, which is N-PEGylated NP-10 linked to PEGylated biotin via 1,2,3-triazole moiety (code 
number HMI1345); 1-(1-(13-oxo-17-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6,9-trioxa-
12-azaheptadecyl)-1H-1,2,3-triazol-4-yl)-2,5,8,11-tetraoxatridecan-13-yl (Z)-N-((E)-(9-ethyl-9H-carbazol-3-yl)
methylene)-4-iodobenzohydrazonate, which is O-PEGylated NP-14 linked to PEGylated biotin via 1,2,3-triazole 
moiety (code number SBT171); and N-(2-(2-(2-(2-(4-((E)-1-(9-ethyl-9H-carbazol-3-yl)-3-(4-iodobenzoyl)-
6,9,12,15-tetraoxa-2,3-diazahexadec-1-en-16-yl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-5-
((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide, which is N-PEGylated NP-14 linked 
to PEGylated biotin via 1,2,3-triazole moiety (code number SBT-170). The synthesis procedure is described in 
Supplemental Information.
In addition, 19 NP-10 derivatives were synthesized including N′-[(9-ethyl-9H-carbazol-3-yl)methyl-
ene]-2-chlorobenzohydrazide (code number HMI83-2). The synthesis procedure is described in Supplemental 
Information.
Identification of NP-10-binding proteins from HeLa cell lysates by pull-down assay with 
biotinylated compounds. The biotinylated compounds were mixed with Streptavidin Sepharose High 
Performance (GE Healthcare, 17-5113-01) in buffer A [50 mM Tris-HCl (pH 7.5), 50 mM KCl, 5 mM MgCl2, and 
1 mM EDTA]. HeLa cell lysates were harvested from a 10 mL culture, resuspended in 1 mL of buffer B [buffer A 
containing 1 mM DTT, protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 12 μg/mL aprotinin, and 1/100 
protease inhibitor cocktail from Nacalai Tesque), and phosphatase inhibitors (5 mM sodium fluoride and 10 mM 
β-glycerophosphate)], and sonicated for 10 s eight times on ice using Bioruptor (Cosmo Bio Co., Ltd.). The soluble 
fraction was separated by centrifugation at 15000 rpm for 15 min and incubated with compound-immobilized 
beads for 4 h at 4 °C. The beads were washed three times with wash buffer (buffer A containing 0.1% NP-40 and 
100 mM KCl), and bound proteins were eluted with 1 × SDS sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 
5% β-mercaptoethanol, 10% glycerol, and 0.01% bromophenol blue) and subjected to SDS-PAGE followed by 
mass spectrometry analysis or immunoblotting.
Mass spectrometry analysis. The bound proteins were resolved by SDS-PAGE followed by Coomassie 
Brilliant Blue staining to visualize protein bands. The stained bands were excised and proteins in each gel slice 
were reduced, alkylated, and digested with trypsin (Promega) in 50 mM ammonium bicarbonate for 16 h at 37 °C. 
The generated peptides were then subjected to an ultra-high performance liquid chromatography system (AMR) 
Figure 2. Transformed HFF2/T/E7/KRAS G12V cells are hypersensitive to NP-10 compared with parental 
HFF2/T cells. Parental HFF2/T and HFF2/T/E7/KRAS G12V cells were subjected to colony formation assays 
in the presence of NP-10 at various concentrations, and the IC50 values were calculated. Data represent the 
mean ± SD from multiple independent experiments (n = 4 for HFF2/T, n = 3 for HFF2/T/E7/KRAS G12V). 
**p < 0.01 (two-tailed Student’s t-test).
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Figure 3. Pull-down assay with biotin-conjugated compounds. (A) Chemical structures of biotinylated 
compounds. O-PEGylated NP-10 (R1 = I, R2 = H) or NP-14 (R1 = H, R2 = I) linked to PEGylated biotin via 
the 1,2,3-triazole moiety (upper panel) and N-PEGylated NP-10 or NP-14 linked to PEGylated biotin via the 
1,2,3-triazole moiety (lower panel) are shown. (B) O-PEGylated, but not N-PEGylated, NP-10 and NP-14 
(without 1,2,3-triazole and PEGylated biotin) induce G2/M arrest in HeLa cells. HeLa cells were treated with 
vehicle (DMSO) or the indicated compounds (10 μM) for 24 h. After staining with propidium iodide, cell cycle 
distribution was analyzed by flow cytometry (upper panels). In vitro inhibition of HeLa cell growth by the 
compounds was also investigated (lower panel). The IC50 (50% inhibition concentration) values were estimated. 
Data represent the mean from two independent experiments. (C) HeLa cell lysates were incubated with the O-
biotinylated (active) or N-biotinylated (inactive) NP-10 beads immobilized by biotin-avidin interaction. The 
pulled-down proteins were analyzed by SDS-PAGE and Coomassie Brilliant Blue (CBB) staining. The gel was 
cut into eight fractions as shown on the right. Proteins in each gel fraction were identified by mass spectrometry 
analysis.
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followed by a Q Exactive mass spectrometer (Thermo Fisher Scientific). Obtained raw data were compared with 
the SwissProt Homo sapiens database using Proteome Discoverer 1.4 (Thermo Fisher Scientific) with the Mascot 
search engine version 2.4 (Matrix Science).
Immunoblot analysis and antibodies. Immunoblotting was performed as described previously7. 
Antibodies used in this study were as follows: NUP155 (A303-934A, Bethyl Laboratories), IPOβ (ab2811, Abcam), 
KNTC1 (F2051-10H4, Sigma-Aldrich), hCAP-D2 (E4161-4C12, Sigma-Aldrich), IPO7 (ab88339, Abcam), CLTC 
(sc-271178, Santa Cruz), Cdc2-phosphorylated vimentin Ser55 (D076-3, MBL), GST (G7781, Sigma-Aldrich), 
GFP (A6455, Invitrogen), and HA-tag (clone 3F10, Roche). Secondary antibodies were HRP-rabbit anti-mouse 
IgG (H + L) (61-6520, Invitrogen) or HRP-goat anti-rabbit IgG (H + L) (65–6120, Invitrogen).
siRNA experiments. siRNA oligonucleotides (IDT) with the following sequences (sense strand) were syn-
thesized: siNUP155-1 (5′-GCAUGUCAGAUAUGGAUUAUCCUdTdT-3′), siNUP155-2 (5′-GGCAUCUAC 
UUGUGAGUAAUGUGdGdG-3′), siIPOβ-1 (5′-GGCGGAGAUCGAAGACUAACAAAdGdC-3′), siIPOβ-2 
(5′-AGAAGAGCCUAGUAAUAAUGUGAdAdG-3′), siKNTC1-1 (5′-AGCUCAUAGAUAAAGCAUGG 
CAGdAdA-3′), siKNTC1-2 (5′-AGAAAGGAAUGACAGUUAAGAACdCdT-3′), sihCAP-D2-1 (5′-GGCAAGG 
CUAUAAUAGAUGAAUUdTdG-3′), sihCAP-D2-2 (5′-GGCAGACAAGUCAGUGCUAGUAUdGdT
-3 ′),  siIPO7-1 (5 ′-GCCUUAGAGCUAACAAGAAGAUGdTdC-3 ′),  siIPO7-2 (5 ′-AGAAGACC 
CUUACGAAUAUAUACdGdC-3′), control siLuci (5′-GGUUCCUGGAACAAUUGCUUUUAdCdA-3′), and 
control siGFP (5′-ACCCUGAAGUUCAUCUGCACCACdCdG-3′). HeLa cells (1 × 105/well) seeded in 12 well 
plates were transfected with 18 pmol siRNA duplexes using Lipofectamine RNAiMAX (Invitrogen) for 48 h. The 
procedure used for co-transfection of siRNA and expression vector is described below.
Plasmids. pGEX-6P-2-NUP155 N, pGEX-6P-1-NUP155 M, and pGEX-6P-2-NUP155 C were generated by 
inserting NUP155 truncated mutants (encoding amino acids [aa] 1–548, 509–992, and 960–1391, respectively) 
prepared from pBluescriptR-NUP155 (GE Healthcare) into pGEX-6P-1 or pGEX-6P-2 (GE Healthcare) using the 
In-Fusion HD cloning system (Clontech). pGEX-6P-2-IPOβ N and pGEX-6P-2-IPOβ C were similarly generated 
by inserting IPOβ truncated mutants (aa 1–450 and 450–876, respectively) prepared from pOTB7-IPOβ (GE 
Healthcare) into pGEX-6P-2.
The following primers were used: for NUP155 N, 5′-CCAGGAATTCCCGGGATGCCGTCTTCTTTGTTG 
GGCG-3′ (NUP155 N forward) and 5′-ATGCGGCCGCTCGAGCACAAGCCTGGTCTTCC-3′ (NUP155 
N reverse); for NUP155 M, 5′-GGAATTCCCGGGTCGCTCAGCACAGGGGAGCCTTATG-3′ (NUP155 
M forward) and 5′-ATGCGGCCGCTCGAGGAGACTGAGGAGCGGCC-3′ (NUP155 M reverse); for 
NUP155 C, 5′- CCAGGAATTCCCGGGGTTGGACTTCAGGCCTTCC-3′ (NUP155 C forward) and 
5′-ATGCGGCCGCTCGAGCGGATCAGGCCCTTATGGC-3′ (NUP155 C reverse); for IPOβ N, 5′-CCAGG 
AAT TCCCGGGATGGAGCTGATCACCAT TCTCG-3 ′  ( IPOβ  N for ward)  and 5 ′ -ATGCGG 
CCGCTCGAGAGCCAAGTAGACATCATTGATGGC-3′ (IPOβ N reverse); and for IPOβ C, 5′-CCA 
GGAATTCCCGGGCCCCTGCTACAGTGTCTGATTG-3 ′  (IPOβ  C forward) and 5 ′-ATGCGG 
CCGCTCGAGTGGGGGTCCTCAGGTTATCATC-3′ (IPOβ C reverse).
pEGFP-C1-IPOβ was constructed by inserting IPOβ cDNA into pEGFP-C1 (Clontech) using the 
In-Fusion HD cloning system. The following primers were used: 5′-TCCGGACTCAGATCTGAGC 
TGATCACCATTCTCGAGAAG-3′ (IPOβ forward) and 5′-AGATCCGGTGGATCCTCAAGCTTG 
GTTCTTCAGTTTCCT-3′ (IPOβ reverse). pFLAG-CMV-5b-HA-IPO7 was constructed by inserting IPO7 
cDNA [prepared from pCR-Blunt II-TOPO-IPO7 (ThermoFisher Scientific)] into Not I- and Sma I-digested 
(to remove FLAG-GRWD1) pFLAG-CMV-5b-HA-GRWD16 using the In-Fusion HD cloning system. The fol-
lowing primers were used: 5′-CCAGACTATGCGGCCGGAGACCCCAACAACATTATCGA-3′ (IPO7 forward) 
and 5′-ACAGGGATGCCACCCGGGTCAATTCATCCCTGGTGCT-3′ (IPO7 reverse). pEGFP-C1-NUP155 MC 
was constructed by inserting NUP155 truncated mutant (aa 748–1391) into pEGFP-C1 using the In-Fusion HD 
cloning system. The following primers were used: 5′-TCCGGACTCAGATCTATGCGTCCTGAAAACGGAAAT
-3′ (NUP155 MC forward) and 5′-AGATCCGGTGGATCCATGAAGCCGTTCTAATTTAGC-3′ (NUP155 MC 
reverse).
Transfection. For Fig. 4, expression plasmids (0.5 μg) and siRNA (12 pmol) were transiently transfected into 
1 × 105 HeLa cells in 12-well plates using Lipofectamine 2000 (Invitrogen). After 16 h, cells were fed with fresh 
medium for immunoblotting or replated in 4-well chamber slides (LAB-TEK, Thermo Fisher) at a density of 
1.67 × 105 cells/well for microscopic analysis. At 48 h post-transfection, cells were used for analyses.
For Supplementary Fig. S3, expression plasmids (0.8 μg) were transiently transfected into 1 × 105 HeLa 
and 293T cells in 12-well plates using PEImax (Polysciences). At 48 h post-transfection, cells were subjected to 
immunoblotting.
For Fig. 1A, expression plasmids (1.6 μg) were transiently transfected into 1 × 105 HeLa cells in 12-well plates 
using Lipofectamine 2000 (Invitrogen). After 48 h, cells were subjected to immunoblotting.
For Fig. 1B, expression plasmids (3.0 μg) were transiently transfected into 2 × 105 HeLa cells in 35 mm dishes 
using Lipofectamine 2000 (Invitrogen). After 24 h, cells were subjected to clonogenic assay.
Pull-down assay of recombinant NUP155 and IPOβ with the biotinylated compounds. GST-NUP155 
N, GST-NUP155 M, GST-NUP155 C, GST-IPOβ N, and IPOβ C were bacterially expressed and purified on glutathione 
beads as described previously6. Streptavidin Sepharose bound to biotinylated compounds was incubated with the puri-
fied proteins for 1 h at 4 °C. Beads were washed three times with wash buffer 1 (buffer A containing 0.02% NP-40 and 
200 mM KCl) for NUP155 or wash buffer 2 (buffer A containing 0.1% NP-40 and 200 mM KCl) for IPOβ, and the 
bound proteins were eluted with 1 × SDS sample buffer, followed by SDS-PAGE and immunoblotting.
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Microscopic analysis. For Fig. 4B, cells were fixed with 3.7% formaldehyde in PBS for 10 min at room tem-
perature (RT) and further treated with 100% ice-cold MeOH for 15 min. The cells were then permeabilized with 
0.1% Triton X-100 in PBS for 10 min at RT and counterstained with 4,6-diamidino-2-phenylindole (DAPI). Cells 
were finally mounted in Fluoro-KEEPER Antifade Reagent (Nacalai Tesque) and analyzed using a KEYENCE 
BZ-9000 microscope.
Tumor studies in nude mice. Tumor studies in nude mice were performed essentially as described previ-
ously5. The protocols for animal experiments were approved by Kyushu University Animal Care and Use 
Committee (permit number: A23-067 and A25-023). All animal experiments were performed in accordance with 
the relevant national and international guidelines contained in the ‘Act on Welfare and Management of Animals’ 
(Ministry of Environment of Japan) and ‘Regulation of Laboratory Animals’ (Kyushu University). Four-week-old 
female BALB/c nu/nu nude mice were obtained from Kyushu Co., Ltd. Mice were inoculated by subcutaneous 
injection on the back with 4 × 105 HCT116 cells mixed with Matrigel (50 μL of cell suspension + 50 μL of 
Matrigel, 356234, BD Biosciences). The size of the tumor was examined using digital calipers, and the volume was 
Figure 4. Overexpression of GFP-IPOβ and silencing of NUP155 induce mitotic arrest. (A) HeLa cells 
were co-transfected with the indicated expression vectors and siRNAs for 48 h, and immunoblotted with the 
indicated antibodies. (B) HeLa cells transfected as in (A) were stained with DAPI and analyzed by fluorescence 
microscopy. Representative images of mitotic cells are shown. Scale bar, 10 μm. Percentages of mitotic cells with 
GFP signals are depicted. *p < 0.05, **p < 0.01, ***p < 0.001 (χ2-test). Similar results were obtained in two 
independent experiments.
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calculated using the following formula: tumor volume (mm3) = length × (width) 2 × π/6. Body weight and tumor 
size were measured three times per week. Once the tumor reached approximately 100 mm3, mice were randomly 
divided into two groups, one treated with the control vehicle mixture detailed below and the other treated with 
vehicle containing HMI83-2 (100 mg/kg). The indicated drug was administered intraperitoneally seven times as 
indicated in Fig. 5B. The vehicle mixture consisted of 40% hydroxypropyl-β-cyclodextrin (HP-β-CyD), 30% 
PEG400, 20% ethanol, and 10% DMSO.
Data presentation and statistical analysis. Data presentation and statistical analysis was performed 
essentially as described previously6. Unless otherwise stated, quantitative data are shown as the mean ± SD from 
three or more independent experiments. For presentation of qualitative and semi-quantitative data, a represent-
ative image is displayed. For all such data, essentially the same results were observed in the multiple independent 
experiments. Unless otherwise stated, the statistical significance of differences between two groups was estimated 
by a two-tailed Student’s t-test. P values < 0.05 were considered statistically significant.
The statistical significance of the differences among more than two groups was first examined by one-way 
ANOVA test. Then, the difference between two groups was analyzed using the Tukey-Kramer multiple compari-
son test. P values < 0.05 were considered statistically significant.
Results and Discussion
Comprehensive identification of NP-10-interacting proteins. For affinity purification of NP-10-
binding proteins, we prepared O-PEGylated or N-PEGylated NP-10 linked to PEGylated biotin via the 1,2,3-tri-
azole moiety and O-PEGylated or N-PEGylated NP-14 linked to PEGylated biotin via the 1,2,3-triazole moiety 
(Fig. 3A and Materials and Methods). First, we determined whether these compounds had antimitotic effects 
comparable to those of the original NP-10 and NP-14 molecules5. Flow cytometry analysis showed that 
O-PEGylated NP-10 and NP-14 (without 1,2,3-triazole and PEGylated biotin), but not N-PEGylated NP-10 and 
Figure 5. HMI83-2 suppresses the growth of HCT116 tumors in nude mice. (A) Chemical structure of HMI83-
2. (B) HCT116 cells were subcutaneously inoculated into BALB/c nu/nu nude mice. The mice were treated with 
100 mg/kg of HMI83-2 or control vehicle (n = 7, n = 6 respectively), as described in Materials and Methods. 
The mean tumor volumes (with SDs) are shown. Arrows represent the days of drug administration. *p < 0.05 
(compared with vehicle; two-tailed Student’s t-test). (C) Kaplan–Meier curves obtained with the experiments 
shown above. *p < 0.05 (compared with vehicle; log-rank test). (D) Changes in body weight of the nude mice 
treated with HMI83-2 or control vehicle are shown.
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NP-14, induced G2/M arrest and inhibited the growth of HeLa cells at concentrations comparable to those of the 
original compounds (Fig. 3B). Therefore, O-PEGylated NP-10 and NP-14 are hereafter referred to as the active 
forms and N-PEGylated NP-10 and NP-14 as the inactive forms. Biotinylated NP-10 was immobilized onto avi-
din-coated beads, and bound proteins were purified from HeLa cell lysates. Proteins were eluted using SDS and 
subjected to SDS-PAGE (Fig. 3C) followed by mass spectrometry. Among proteins identified using active NP-10 
beads, those showing Mascot scores >200 and ≥2-fold higher than those of the control samples were selected 
(Supplementary Fig. S1).
The following proteins were selected for further analysis for the reasons listed: importin 7 because it had the 
highest Mascot score (2820); importin β because it showed a high Mascot score (1246) and because previous 
reports suggest that it is involved in regulating mitotic progression8–11; NUP155 because of the high Mascot score 
(820) and the potential involvement of nuclear pore proteins in mitotic regulation8,12; KNTC1 because of its high 
Mascot score (768) and probable involvement in mitotic regulation13; and hCAP-D2 because of a high Mascot 
score (547) and probable involvement in mitotic regulation14,15.
Binding of the selected proteins to active O-biotinylated NP-10 beads was confirmed by pull-down assay and 
immunoblotting. As shown in Fig. 6A, all selected proteins bound to active O-biotinylated NP-10 more efficiently 
than to inactive N-biotinylated NP-10. These proteins also bound to active O-biotinylated NP-14 (Fig. 6A). We 
previously showed that NP-14, but not NP-10, inhibits tubulin polymerization in vitro5. Thus, it is possible that 
NP-10 with an iodo moiety at the ortho position of the benzene ring and NP-14 with an iodo moiety at the para 
position5 (see also Fig. 3A) share target proteins, whereas the latter also targets tubulin.
Silencing of NUP155, an NP-10-interacting protein, induces mitotic arrest. Because NP-10 could 
act as an antagonist against the identified proteins, we designed siRNAs against them and examined the effect of 
silencing on mitotic arrest. For this purpose, we measured the levels of phospho-vimentin Ser-55, which is phos-
phorylated by Cdk1, or phospho-histone H3 Ser-10, which is phosphorylated by Aurora B, as mitotic markers5. 
As shown in Figs 6B and S2, silencing of NUP155, but not the other factors including importin β and the closely 
related importin 7, induced mitotic arrest. The induction of mitotic arrest by NUP155 silencing was confirmed 
by flow cytometry (Fig. 6C).
Overexpression of importin β, another NP-10-interaction protein, inhibits mitotic progression 
and the effect is enhanced by silencing NUP155. Overexpression of importin β affects the localization 
of certain MAPs, leading to aberrant spindle formation and delayed mitotic progression11. Because importin β 
and importin 7 efficiently bind to NP-10, we hypothesized that NP-10 may have an agonistic effect on importin 
β and/or importin 7. To test this hypothesis, we examined the effect of importin β and importin 7 overexpression 
on mitotic progression. Consistent with previous findings, overexpression of GFP-importin β (Fig. 4A) resulted 
in the accumulation of mitotic cells (Fig. 4B). Overexpression of importin 7 did not increase the number of 
mitotic cells, confirming that the effect was specific to importin β (Supplementary Fig. S3). Analysis of the effect 
of NUP155 silencing combined with importin β overexpression on mitotic progression showed that silencing of 
NUP155 additively increased the mitotic population in GFP-importin β-overexpressing HeLa cells (Fig. 4).
Purified NUP155 and importin β directly bind to active NP-10. To determine whether purified 
NUP155 and importin β bind to active NP-10 directly, we prepared three fragments covering full-length NUP155 
(NUP155 N-terminal, mid, and C-terminal fragments; Fig. 7A) and two fragments covering full-length importin 
β (importin β N-terminal and C-terminal fragments; Fig. 7A), and investigated their binding to active or inactive 
NP-10 beads. As shown in Fig. 7B, NUP155 C-terminal fragment and importin β C-terminal fragment specif-
ically bound to the active form of NP-10. NUP155 mid fragment showed some binding to active NP-10 beads, 
although to a similar extent as to inactive NP-10 beads.
Overexpression of NUP155 confers partial resistance to NP-10 cytotoxicity in HeLa cells. To con-
firm that  NUP155 contributes to the effect of NP-10 on inducing mitotic arrest, we examined the effect of overexpres-
sion of NUP155 MC fragment (aa 748–1391), which includes the NP-10-binding regions, on drug sensitivity in HeLa 
cells. As shown in Fig. 1, overproduction of NUP155 MC decreased the cytotoxicity of NP-10 in HeLa cells. Taken 
together, these data supported the notion that NP-10 acts as an agonist to importin β and an antagonist to NUP155. 
However, it is possible that NP-10 affects other molecule(s) to induce efficient mitotic arrest in cancer cells.
Transformed HFF2/T/E7/KRAS G12V cells are hypersensitive to NP-10 compared with paren-
tal HFF2/T cells. The molecular mechanism underlying the tumor cell-selective inhibitory effect of NP-10 
remains unclear5. Recent studies suggest that cancer cells are under a higher replication stress than normal 
cells because of oncogenic hypergrowth stimuli16,17. Although the mechanism of the hyper-replication stress is 
unclear, collision between DNA replication and transcription, both of which are promoted by oncogenic stim-
uli, may occur more frequently in cancer cells17. Such collisions may stall replication forks, thereby causing 
hyper-replication stress. Replication stress also causes mitotic aberrations such as chromatin bridges, lagging 
chromosomes, and ultrafine bridges18,19. Therefore, we hypothesized that oncogenic hyperstimulation affects the 
sensitivity to NP-10. To test this hypothesis, we prepared normal human HFF2/T fibroblasts (immortalized by 
telomerase) and the transformed counterpart HFF2/T/E7/KRAS cells, which contain the activated KRAS mutant 
G12V and the E7 of human papilloma virus type 16 (HPV16)6,20, and investigated their sensitivity to NP-10. The 
results showed that transformed HFF2/T/E7/KRAS cells were hypersensitive to NP-10 (Fig. 2), which supported 
our hypothesis. However, other mechanism(s) may also contribute to the cancer cell selectivity of NP-10 as sug-
gested previously5.
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Synthesis and evaluation of the antimitotic activity of NP-10 derivatives. In previous work, we 
did not observe in vivo antitumor activity of NP-105, possibly due to poor in vivo stability of the iodo moiety (for 
detail, see a review article by Cavina et al.21) in NP-10. To obtain more effective NP-10-related compounds, we 
synthesized 19 NP-10 derivatives with different substituents on the benzoyl and carbazole moieties to understand 
the structure-activity relationship (SAR) (Fig. 8). Flow cytometric analysis was used to examine whether the 
compounds induced G2/M arrest in HeLa cells at 10 μM (the original NP-10 induces G2/M arrest at 10 μM5). 
Of the 19 compounds, 11 induced G2/M arrest (Fig. 8), and the SAR suggested that ethyl group on the carbazole 
nitrogen atom may be important for the activity. The IC50 of these compounds was determined by examining their 
effect on the growth of cervical cancer-derived HeLa cells and telomerase-immortalized normal human fibroblast 
HFF2/T cells (Fig. 8). In addition, we calculated the ratio between the IC50 for HFF2/T and the IC50 for HeLa as a 
cancer cell selectivity index5 (Fig. 8). The activity of the 11 compounds was comparable to that of NP-10, with IC50 
values of 1.88–8.68 μM and selectivity indexes of 1.55–6.12 (Fig. 8). The SAR for the IC50 and the selectivity index 
suggested that the selectivity index may be better for the derivatives with substituent at the ortho position of the 
benzoyl moiety, whereas IC50 may be smaller when the substituent is present at the para position.
Figure 6. Silencing of NUP155, a potential target of NP-10, induces mitotic arrest. (A) HeLa cell lysates 
were incubated with avidin beads on which the indicated compounds were immobilized. The bound proteins 
and 5.4% of the input were analyzed by immunoblotting with the indicated antibodies. (B) HeLa cells were 
transfected with control (mixture of siGFP and siLuci) or NUP155-targeting (siNUP155-1 or siNUP155-2) 
siRNAs for 48 h. Whole cell extracts were analyzed by immunoblotting with the indicated antibodies. Phospho-
vimentin (Ser55), a target of Cdk1 kinase, was used as a mitotic marker. Proteins were stained with Coomassie 
Brilliant Blue (CBB) to check equal loading. (C) HeLa cells treated as above were stained with propidium iodide 
and subjected to flow cytometry.
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Figure 7. Identification of NP-10-binding domains for IPOβ and NUP155. (A) Schematic representation 
of full-length NUP155 and IPOβ (FL) and their truncated mutants. The N-terminal and C-terminal parts of 
NUP155 have predicted β-propeller and α-solenoid structures, respectively. The N-terminal and C-terminal 
parts of IPOβ are RanGTP and IPOα binding domains, respectively. (B) GST, GST-IPOβ mutants, or NUP155 
mutants were incubated with active or inactive NP-10-immobilized beads (through biotin-avidin interaction). 
The pulled-down proteins, 3.5% of the input for GST-NUP155 mutants, and 5.8% of the input for GST and 
GST-IPOβ mutants were analyzed by immunoblotting with anti-GST antibody. Biotin-conjugated PEG linker 
was used as a negative control. The signal intensities of the bands were quantified and shown with the signal 
intensities of inputs set as 1. The mean ± SD is shown (n = 3 for NUP155 N and IPOβ N; n = 4 for NUP155 M; 
n = 5 for NUP155C and IPOβ C). **p < 0.01, n.s., not significant (Tukey-Kramer test).
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HMI83-2, an NP-10-related compound with a Cl moiety, inhibits HCT116 cell tumor formation in 
nude mice. Based on the in vitro data (Fig. 8) and the fact that the I and CH3 moieties are generally unstable (for 
detail, see review articles21–23), we selected N′-[(9-ethyl-9H-carbazol-3-yl)methylene]-2-chlorobenzohydrazide (code 
number HMI83-2) (Fig. 5A) for further study. HMI83-2 shows relatively high growth inhibitory activity against HeLa 
cells with relatively high selectivity index and has chloro moiety instead of the iodo moiety. We examined the in vivo 
antitumor activity of HMI83-2 using a HCT116 cell xenograft model in nude mice.
Nude mice bearing HCT116 cell tumors were treated with control vehicle or HMI83-2 (100 mg/kg) seven 
times as indicated in Fig. 5B (intraperitoneal injection). HMI83-2 exhibited a statistically significantly higher 
antitumor effect than the control under these experimental conditions (Fig. 5B,C) without significant loss of 
body weight (Fig. 5D), suggesting that in addition to HND-007, another NP-10-related compound5, HMI83-2 is 
a promising lead compound for the development of novel antimitotic agents.
Data availability
The datasets generated during and/or analysed during the current study and materials used in the current study 
are available from the corresponding author on reasonable request.
Figure 8. Growth inhibitory activities of various NP-10-related compounds. Chemical structures of NP-10 
derivatives and their growth inhibitory activities. The IC50 unit was μM. The selectivity index is the ratio 
between the IC50 for HFF2/T cells and the IC50 for HeLa cells. ND, not determined.
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